CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Analyst Reco. Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 05/12/2025 GMT			5-day change	1st Jan Change
184.31 ^USD	+0.15%		+3.46%	-0.16%

12-03	Charles River Laboratories International, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10:00 AM
12-03	Charles River Laboratories International Inc - DSA Net Book-to-Bill Improved Each Month Since Q3 2025 - SEC Filing	RE

Analyst Reco.

Jefferies Adjusts PT on Charles River Laboratories International to $205 From $200, Maintains Buy Rating	12-02	MT
Argus Upgrades Charles River Laboratories International to Buy From Hold, Price Target is $200	11-17	MT
Morgan Stanley Adjusts Charles River Laboratories International PT to $185 From $170, Maintains Equal Weight Rating	11-11	MT
TD Cowen Adjusts Price Target on Charles River Laboratories International to $197 From $205	11-10	MT
JPMorgan Adjusts Price Target on Charles River Laboratories International to $165 From $160, Maintains Neutral Rating	11-06	MT
Jefferies Adjusts Price Target on Charles River Laboratories International to $200 From $195, Maintains Buy Rating	11-06	MT
Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $195, Maintains Overweight Rating	11-06	MT
Baird Upgrades Charles River Laboratories International to Outperform From Neutral, Adjusts PT to $199 From $178	11-06	MT
BofA Adjusts Price Target on Charles River Laboratories International to $190 From $175	10-20	MT
Mizuho Securities Adjusts Charles River Laboratories International Price Target to $174 From $155, Maintains Neutral Rating	10-17	MT
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $205 From $185, Maintains Buy Rating	10-16	MT
TD Cowen Adjusts Price Target on Charles River Laboratories International to $205 From $179, Maintains Buy Rating	10-13	MT
Baird Adjusts Price Target on Charles River Laboratories International to $178 From $161, Maintains Neutral Rating	10-13	MT
William Blair Upgrades Charles River Laboratories International to Outperform From Market Perform	10-06	MT
Evercore ISI Adjusts PT on Charles River Laboratories International to $200 From $190, Maintains Outperform Rating	10-03	MT
Charles River Labs Shares Rise After Barclays Upgrade	10-02	MT
Barclays Upgrades Charles River Laboratories International to Overweight From Equalweight	10-02	MT
Baird Adjusts PT on Charles River Laboratories International to $161 From $151, Maintains Neutral Rating	09-15	MT
Jefferies Upgrades Charles River Laboratories International to Buy From Hold, Raises Price Target to $195 From $142	09-09	MT
Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $211 From $189, Maintains Buy Rating	09-03	MT
Rothschild & Co Redburn Adjusts Price Target on Charles River Laboratories International to $189 From $182, Maintains Buy Rating	08-07	MT
Barclays Adjusts Price Target on Charles River Laboratories International to $165 From $155, Maintains Equalweight Rating	08-07	MT
Baird Adjusts Price Target on Charles River Laboratories International to $151 From $140, Maintains Neutral Rating	08-07	MT
JPMorgan Adjusts Price Target on Charles River Laboratories International to $160 From $145, Maintains Neutral Rating	08-07	MT
Morgan Stanley Lifts Price Target on Charles River Laboratories International to $170 From $168, Keeps Equalweight Rating	08-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Analyst Reco.

Filters